STE vs. EW, ALGN, ZBH, SNN, MOH, BAX, ILMN, BNTX, WAT, and GMAB
Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Edwards Lifesciences (EW), Align Technology (ALGN), Zimmer Biomet (ZBH), Smith & Nephew (SNN), Molina Healthcare (MOH), Baxter International (BAX), Illumina (ILMN), BioNTech (BNTX), Waters (WAT), and Genmab A/S (GMAB). These companies are all part of the "medical" sector.
STERIS (NYSE:STE) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.
STERIS has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
94.7% of STERIS shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 1.0% of STERIS shares are held by insiders. Comparatively, 1.3% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Edwards Lifesciences has higher revenue and earnings than STERIS. Edwards Lifesciences is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.
In the previous week, Edwards Lifesciences had 2 more articles in the media than STERIS. MarketBeat recorded 22 mentions for Edwards Lifesciences and 20 mentions for STERIS. Edwards Lifesciences' average media sentiment score of 0.99 beat STERIS's score of 0.37 indicating that Edwards Lifesciences is being referred to more favorably in the news media.
Edwards Lifesciences received 988 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 71.80% of users gave Edwards Lifesciences an outperform vote while only 58.58% of users gave STERIS an outperform vote.
Edwards Lifesciences has a net margin of 23.01% compared to STERIS's net margin of 10.48%. Edwards Lifesciences' return on equity of 22.86% beat STERIS's return on equity.
STERIS currently has a consensus target price of $239.60, indicating a potential upside of 13.99%. Edwards Lifesciences has a consensus target price of $93.27, indicating a potential upside of 9.61%. Given STERIS's higher probable upside, analysts clearly believe STERIS is more favorable than Edwards Lifesciences.
Summary
Edwards Lifesciences beats STERIS on 14 of the 18 factors compared between the two stocks.
Get STERIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
